English

INHIBIKASE THERAPEUTICS, INC.

EDGAR

IKT Current report (8-K) · filed 2026-10-20

Annual consolidated revenue for 2024: about USD 0, using the latest reported figures. The previous period, 2023, was about USD 260.5K.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-12.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24503334 USD Source
Operating Cash Flow: -12059722 USD Source

Free cash flow

-12.4 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -24503334 USD Source
Operating Cash Flow: -12059722 USD Source
Capital Expenditure: 0 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 179 million USD 2025-12-31 Source
Exact value

178800000 USD
Long-term debt including current maturities: 382 thousand USD 2023-12-31 Source
Exact value

381784 USD
Shares outstanding: 132 million shares 2026-06-30 Source
Exact value

132032636 shares

Reported share-count change

77.19% · 57.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

74516635 shares · 2025-06-30· Source
132032636 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-60.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: -11930280 USD · 2025-07-01 – 2025-09-30 Source
Net income: -48259189 USD · 2025-01-01 – 2025-12-31 Source
Net income: -35524538 USD · 2025-01-01 – 2025-09-30 Source
Net income: -16380840 USD · 2026-01-01 – 2026-03-31 Source
Net income: -19591231 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-42.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -20270491 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -9677761 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -27786464 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -20270491 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12059722 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -24503334 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12059722 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

0 USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Capital expenditure: 13399 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Free cash flow

-42.6 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -20270491 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -9677761 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -27786464 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -20270491 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -12059722 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -24503334 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -12059722 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 13399 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-06-30 Source
Capital expenditure: 0 USD · 2026-01-01 – 2026-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-20.

Financial data available through: 2024-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2024-12-31
Operating income: 6 of 11 periods available· newest 2024-12-31
Net income: 6 of 11 periods available· newest 2024-12-31
Operating cash flow: 6 of 11 periods available· newest 2024-12-31
Capital expenditure: 4 of 11 periods available· newest 2024-12-31
Total assets: 6 of 11 periods available· newest 2024-12-31
Total liabilities: 6 of 11 periods available· newest 2024-12-31
Current assets: 6 of 11 periods available· newest 2024-12-31
Current liabilities: 6 of 11 periods available· newest 2024-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2024-12-31
Long-term debt including current maturities: 3 of 11 periods available· newest 2023-12-31
Shares outstanding: 6 of 11 periods available· newest 2024-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 260,501

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 260501 = -260501 USD

260501 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Year-over-year change in Revenue: -260501 USD Concept: fundies:Revenue Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#2380134 Filing: 000095017025046096 Input fundies:Revenue: 260501 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#2381701 Filing: 000095017025046096
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 8.49 million

Prior period

−USD 19.03 million

2023-01-01 – 2023-12-31
Current period

−USD 27.52 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-27519886 − -19028883 = -8491003 USD

-19028883 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-27519886 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Year-over-year change in Net income: -8491003 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -27519886 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#3509232 Filing: 000119312526126371 Input fundies:NetIncome: -19028883 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#2416724 Filing: 000095017025046096
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 1.06 million

Prior period

−USD 18.09 million

2023-01-01 – 2023-12-31
Current period

−USD 19.15 million

2024-01-01 – 2024-12-31

Exact inputs and evidence

-19148067 − -18085043 = -1063024 USD

-18085043 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
-19148067 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Year-over-year change in Operating cash flow: -1063024 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -19148067 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2451172 Filing: 000119312526126371 Input fundies:OperatingCashFlow: -18085043 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1616618 Filing: 000095017025046096
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%

Prior period

USD 14,238

2023-01-01 – 2023-12-31
Current period

USD 0

2024-01-01 – 2024-12-31

Exact inputs and evidence

0 − 14238 = -14238 USD

14238 USD · 2023-01-01 – 2023-12-31
Inspect prior input Prior source
0 USD · 2024-01-01 – 2024-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Year-over-year change in Capital expenditure: -14238 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2460033 Filing: 000119312526126371 Input fundies:CapitalExpenditure: 14238 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1624838 Filing: 000095017025046096
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2024 2024-01-01 – 2024-12-31

Revenue USD 0
Operating costs Derived USD 28.59 million
Operating income −USD 28.59 million
Tax, interest and other Derived −USD 1.07 million
Net income −USD 27.52 million

Cash

Operating cash flow −USD 19.15 million
Capital expenditure USD 0
Free cash flow Derived −USD 19.15 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2019 Operating loss: operating costs were 608% of revenue.
2020 Operating loss: operating costs were 504% of revenue.
2021 Operating loss: operating costs were 576% of revenue.
2022 Operating loss: operating costs were 14,786% of revenue.
2023 Operating loss: operating costs were 7,812% of revenue.
2024 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2019 2019-01-01 – 2019-12-31	1122740	6820888 Derived	-5698148	24835 Derived	-5722983	Unavailable	Source 2019-01-01 – 2019-12-31: 1122740 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -5698148 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -5722983 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -338290 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	698468	3516960 Derived	-2818492	29402 Derived	-2847894	Unavailable	Source 2020-01-01 – 2020-12-31: 698468 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -2818492 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -2847894 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -1129355 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	3100605	17866745 Derived	-14766140	19923 Derived	-14786063	-14297051 Derived	Source 2021-01-01 – 2021-12-31: 3100605 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -14766140 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -14786063 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -14297051 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	123440	18252048 Derived	-18128608	-74453 Derived	-18054155	-17594358 Derived	Source 2022-01-01 – 2022-12-31: 123440 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -18128608 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -18054155 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -17351103 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 243255 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	260501	20350293 Derived	-20089792	-1060909 Derived	-19028883	-18099281 Derived	Source 2023-01-01 – 2023-12-31: 260501 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -20089792 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -19028883 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -18085043 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 14238 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	0	28589068 Derived	-28589068	-1069182 Derived	-27519886	-19148067 Derived	Source 2024-01-01 – 2024-12-31: 0 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -28589068 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -27519886 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -19148067 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2024

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Revenue	1122740	Revenue: 1122740 Open source
20202020-12-31	Revenue	698468	Revenue: 698468 Open source
20212021-12-31	Revenue	3100605	Revenue: 3100605 Open source
20222022-12-31	Revenue	123440	Revenue: 123440 Open source
20232023-12-31	Revenue	260501	Revenue: 260501 Open source
20242024-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2024

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Year over year	No prior comparable period	Revenue: 1122740 Open source
20202020-12-31	Year over year	-37.8%	Revenue: 698468 Open source Revenue: 1122740 Open source
20212021-12-31	Year over year	343.9%	Revenue: 3100605 Open source Revenue: 698468 Open source
20222022-12-31	Year over year	-96%	Revenue: 123440 Open source Revenue: 3100605 Open source
20232023-12-31	Year over year	111%	Revenue: 260501 Open source Revenue: 123440 Open source
20242024-12-31	Year over year	-100%	Revenue: 0 Open source Revenue: 260501 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -7,712% 2023

Net margin -7,304.7% 2023

Free cash flow margin -6,947.9% 2023

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Operating margin	-507.5%	Operating Income: -5698148 Open source Revenue: 1122740 Open source
20202020-12-31	Operating margin	-403.5%	Operating Income: -2818492 Open source Revenue: 698468 Open source
20212021-12-31	Operating margin	-476.2%	Operating Income: -14766140 Open source Revenue: 3100605 Open source
20222022-12-31	Operating margin	-14,686.2%	Operating Income: -18128608 Open source Revenue: 123440 Open source
20232023-12-31	Operating margin	-7,712%	Operating Income: -20089792 Open source Revenue: 260501 Open source
20242024-12-31	Operating margin	Not reported	Operating Income: -28589068 Open source Revenue: 0 Open source
20192019-12-31	Net margin	-509.7%	Net Income: -5722983 Open source Revenue: 1122740 Open source
20202020-12-31	Net margin	-407.7%	Net Income: -2847894 Open source Revenue: 698468 Open source
20212021-12-31	Net margin	-476.9%	Net Income: -14786063 Open source Revenue: 3100605 Open source
20222022-12-31	Net margin	-14,625.9%	Net Income: -18054155 Open source Revenue: 123440 Open source
20232023-12-31	Net margin	-7,304.7%	Net Income: -19028883 Open source Revenue: 260501 Open source
20242024-12-31	Net margin	Not reported	Net Income: -27519886 Open source Revenue: 0 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 1122740 Open source Operating Cash Flow: -338290 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 698468 Open source Operating Cash Flow: -1129355 Open source
20212021-12-31	Free cash flow margin	-461.1%	Revenue: 3100605 Open source Operating Cash Flow: -14297051 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow margin	-14,253.4%	Revenue: 123440 Open source Operating Cash Flow: -17351103 Open source Capital Expenditure: 243255 Open source
20232023-12-31	Free cash flow margin	-6,947.9%	Revenue: 260501 Open source Operating Cash Flow: -18085043 Open source Capital Expenditure: 14238 Open source
20242024-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -19148067 Open source Capital Expenditure: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -19.1M 2024

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Operating cash flow	-338290	Operating Cash Flow: -338290 Open source
20202020-12-31	Operating cash flow	-1129355	Operating Cash Flow: -1129355 Open source
20212021-12-31	Operating cash flow	-14297051	Operating Cash Flow: -14297051 Open source
20222022-12-31	Operating cash flow	-17351103	Operating Cash Flow: -17351103 Open source
20232023-12-31	Operating cash flow	-18085043	Operating Cash Flow: -18085043 Open source
20242024-12-31	Operating cash flow	-19148067	Operating Cash Flow: -19148067 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -19.1M 2024

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: -338290 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: -1129355 Open source
20212021-12-31	Free cash flow	-14297051	Operating Cash Flow: -14297051 Open source Capital Expenditure: 0 Open source
20222022-12-31	Free cash flow	-17594358	Operating Cash Flow: -17351103 Open source Capital Expenditure: 243255 Open source
20232023-12-31	Free cash flow	-18099281	Operating Cash Flow: -18085043 Open source Capital Expenditure: 14238 Open source
20242024-12-31	Free cash flow	-19148067	Operating Cash Flow: -19148067 Open source Capital Expenditure: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

3.8% 2024

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Liabilities / assets	11,837.4%	Total Liabilities: 4528270 Open source Total Assets: 38254 Open source
20202020-12-31	Liabilities / assets	33.8%	Total Liabilities: 4998350 Open source Total Assets: 14782706 Open source
20212021-12-31	Liabilities / assets	9.5%	Total Liabilities: 4054450 Open source Total Assets: 42469999 Open source
20222022-12-31	Liabilities / assets	15.6%	Total Liabilities: 3900896 Open source Total Assets: 24936297 Open source
20232023-12-31	Liabilities / assets	24.3%	Total Liabilities: 3528725 Open source Total Assets: 14506647 Open source
20242024-12-31	Liabilities / assets	3.8%	Total Liabilities: 3733566 Open source Total Assets: 98599846 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

26.37× 2024

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20192019-12-31	Current assets / current liabilities	0.01×	Current Assets: 35381 Open source Current Liabilities: 4252895 Open source
20202020-12-31	Current assets / current liabilities	3.13×	Current Assets: 14782706 Open source Current Liabilities: 4721889 Open source
20212021-12-31	Current assets / current liabilities	10.47×	Current Assets: 42469999 Open source Current Liabilities: 4054450 Open source
20222022-12-31	Current assets / current liabilities	6.59×	Current Assets: 24371122 Open source Current Liabilities: 3695445 Open source
20232023-12-31	Current assets / current liabilities	4.13×	Current Assets: 14211048 Open source Current Liabilities: 3438601 Open source
20242024-12-31	Current assets / current liabilities	26.37×	Current Assets: 98451309 Open source Current Liabilities: 3733566 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 5.72 million Exact value Exact value: -5722983 USD 2019-01-01 – 2019-12-31: -5722983 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2019-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -5722983 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -5722983 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312521188903/ikt-20210331.xml#86650 Filing: 000119312521188903 The citation records this snapshot. The page link may show a newer release later.	−USD 338,290 Exact value Exact value: -338290 USD 2019-01-01 – 2019-12-31: -338290 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2019-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -338290 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -338290 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312521188903/ikt-20210331.xml#87587 Filing: 000119312521188903 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 2.85 million Exact value Exact value: -2847894 USD 2020-01-01 – 2020-12-31: -2847894 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2020-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -2847894 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2847894 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312523021876/d429998ds1.htm#2393646 Filing: 000119312523021876 The citation records this snapshot. The page link may show a newer release later.	−USD 1.13 million Exact value Exact value: -1129355 USD 2020-01-01 – 2020-12-31: -1129355 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2020-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -1129355 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1129355 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312523021876/d429998ds1.htm#2172169 Filing: 000119312523021876 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 14.79 million Exact value Exact value: -14786063 USD 2021-01-01 – 2021-12-31: -14786063 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2021-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -14786063 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14786063 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017023011133/ikt-20221231.htm#3221147 Filing: 000095017023011133 The citation records this snapshot. The page link may show a newer release later.	−USD 14.3 million Exact value Exact value: -14297051 USD 2021-01-01 – 2021-12-31: -14297051 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2021-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -14297051 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -14297051 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017023011133/ikt-20221231.htm#2637314 Filing: 000095017023011133 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-01-01 – 2021-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INHIBIKASE THERAPEUTICS, INC. · 2021-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017023011133/ikt-20221231.htm#2657108 Filing: 000095017023011133 The citation records this snapshot. The page link may show a newer release later.	−USD 14.3 million Calculation and evidence -14297051 − 0 USD Exact free cash flow: -14297051 USD 2021-01-01 – 2021-12-31: -14297051 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INHIBIKASE THERAPEUTICS, INC. · 2021-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Free cash flow: -14297051 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -14297051 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017023011133/ikt-20221231.htm#2637314 Filing: 000095017023011133 Input fundies:CapitalExpenditure: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017023011133/ikt-20221231.htm#2657108 Filing: 000095017023011133 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 18.05 million Exact value Exact value: -18054155 USD 2022-01-01 – 2022-12-31: -18054155 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2022-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -18054155 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -18054155 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017024037160/ikt-20231231.htm#2391775 Filing: 000095017024037160 The citation records this snapshot. The page link may show a newer release later.	−USD 17.35 million Exact value Exact value: -17351103 USD 2022-01-01 – 2022-12-31: -17351103 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2022-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -17351103 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17351103 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017024037160/ikt-20231231.htm#1925423 Filing: 000095017024037160 The citation records this snapshot. The page link may show a newer release later.	USD 243,255 Exact value Exact value: 243255 USD 2022-01-01 – 2022-12-31: 243255 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INHIBIKASE THERAPEUTICS, INC. · 2022-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Capital Expenditure: 243255 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 243255 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017024037160/ikt-20231231.htm#1931947 Filing: 000095017024037160 The citation records this snapshot. The page link may show a newer release later.	−USD 17.59 million Calculation and evidence -17351103 − 243255 USD Exact free cash flow: -17594358 USD 2022-01-01 – 2022-12-31: -17351103 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 243255 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INHIBIKASE THERAPEUTICS, INC. · 2022-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Free cash flow: -17594358 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17351103 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017024037160/ikt-20231231.htm#1925423 Filing: 000095017024037160 Input fundies:CapitalExpenditure: 243255 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017024037160/ikt-20231231.htm#1931947 Filing: 000095017024037160 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 19.03 million Exact value Exact value: -19028883 USD 2023-01-01 – 2023-12-31: -19028883 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2023-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -19028883 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -19028883 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#2416724 Filing: 000095017025046096 The citation records this snapshot. The page link may show a newer release later.	−USD 18.09 million Exact value Exact value: -18085043 USD 2023-01-01 – 2023-12-31: -18085043 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2023-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -18085043 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -18085043 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1616618 Filing: 000095017025046096 The citation records this snapshot. The page link may show a newer release later.	USD 14,238 Exact value Exact value: 14238 USD 2023-01-01 – 2023-12-31: 14238 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INHIBIKASE THERAPEUTICS, INC. · 2023-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Capital Expenditure: 14238 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 14238 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1624838 Filing: 000095017025046096 The citation records this snapshot. The page link may show a newer release later.	−USD 18.1 million Calculation and evidence -18085043 − 14238 USD Exact free cash flow: -18099281 USD 2023-01-01 – 2023-12-31: -18085043 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 14238 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INHIBIKASE THERAPEUTICS, INC. · 2023-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Free cash flow: -18099281 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -18085043 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1616618 Filing: 000095017025046096 Input fundies:CapitalExpenditure: 14238 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000095017025046096/ikt-20241231.htm#1624838 Filing: 000095017025046096 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 27.52 million Exact value Exact value: -27519886 USD 2024-01-01 – 2024-12-31: -27519886 USD Inspect Net Income Open source Share or cite Citation for Net Income · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Net Income: -27519886 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -27519886 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#3509232 Filing: 000119312526126371 The citation records this snapshot. The page link may show a newer release later.	−USD 19.15 million Exact value Exact value: -19148067 USD 2024-01-01 – 2024-12-31: -19148067 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Operating Cash Flow: -19148067 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19148067 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2451172 Filing: 000119312526126371 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2024-01-01 – 2024-12-31: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2460033 Filing: 000119312526126371 The citation records this snapshot. The page link may show a newer release later.	−USD 19.15 million Calculation and evidence -19148067 − 0 USD Exact free cash flow: -19148067 USD 2024-01-01 – 2024-12-31: -19148067 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · INHIBIKASE THERAPEUTICS, INC. · 2024-12-31 INHIBIKASE THERAPEUTICS, INC. (edgar:1750149) Free cash flow: -19148067 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T05:33:31Z Snapshot: 35801a0e04c3fa94d6bb81ac78f45d4f0bb4e9eb4493931680698238f7fa5436 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1750149?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19148067 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2451172 Filing: 000119312526126371 Input fundies:CapitalExpenditure: 0 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1750149/000119312526126371/ikt-20251231.htm#2460033 Filing: 000119312526126371 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

35 filings · 1,477 latest values · 1,477 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001750149, 1750149, IKT, edgar:1750149

Also known as INHIBIKASE THERAPEUTICS, INC., Inhibikase Therapeutics, Inc.

INHIBIKASE THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2024 2024-01-01 – 2024-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation